In this external validation study, the PDxBR digital prognostic model demonstrated robust performance in stratifying recurrence risk among patients with early-stage HR+/HER2- breast cancer treated according to ESMO and Dutch national guidelines. Here, ERBB2 is linked to breast cancer.